BCAB · BioAtla, Inc.
$1.69
-0.05 (-2.59%)
At close · Aug 31
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Management's assessment concluded that there is substantial doubt about the Company's ability to continue as a going concern for a period of at least one year from the issuance date of these condensed consolidated financial statements.”View the 10-Q filed Aug 13, 2026
Market Cap
$2.89M
Shares
1.67M
Volume · Aug 31
130.29K
Avg daily vol (3M)
80.45K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.69
Open$1.76
Day$1.31–2.13
52W close$1.69–61.00
Avg vol 30d100K
Short int139K · 8.3% float · 2.0d
Short vol35%
Last earningsNov 13, 2025
DataDec 2020–Aug 2026
Filing10-Q · Aug 13
Up next
filed Aug 13, 2026
call held Nov 13, 2025
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$0
Trailing 12 months
Net income (TTM)
−$31.45M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
-32,146.7%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$1.54M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+42.0%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
—
Latest settlement
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Bearish
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.59
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−87%
below
Price vs 50-day avg
−52%
below
RSI (14)
20
oversold
MACD trend
Negative
52-week position
0%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−48%
trailing
6-month return
−80%
trailing
YTD return
−94%
this year
Relative strength
−94%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $3 › 200d $13 — 200d above 50d
Institutional flow
Distributing
-42% holders QoQ · +4 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
8.34% of float · ▲ +31.7% MoM · 2.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
21 holders — near 3-yr low, contrarian setup
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
140%
annualized · 1-yr
Max drawdown
−97%
past year
ATR
27.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−87%
Bearish
Price vs 50-day avg
−52%
Bearish
RSI (14)
20
Neutral
MACD trend
Negative
Bearish
52-week position
0%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $3 › 200d $13 — 200d above 50d
Institutional flow
Distributing
-42% holders QoQ · +4 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
8.34% of float · ▲ +31.7% MoM · 2.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
21 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $2
Now $2 · 0%
Range high $61
vs 200-day avg -87%
vs 50-day avg -52%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BCAB
this stock
BioAtla, Inc.
|
$2.89M | — | — | — | 8.3% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +544.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BCAB | -48.5% | -48.2% | -80.4% | -48.6% | -94.1% |
| SPY | +0.5% | +1.2% | +13.3% | +2.7% | +12.5% |
| vs SPY | -49.0% | -49.4% | -93.6% | -51.3% | -106.5% |